OTC drugs-of-abuse test policy will be "re-examined" -- FDA tells Congress.
This article was originally published in The Tan Sheet
FDA ADVISORY PANEL TO "RE-EXAMINE" POLICY FOR OTC DRUGS-OF-ABUSE TESTS, which are currently considered Class III medical devices, Bruce Burlington, director of the agency's Center for Devices and Radiological Health, said at a Sept. 26 House Commerce/oversight subcommittee hearing. Responding to Rep. Ron Klink (D-Penn.), Burlington said, "We, in fact, do need to re-examine" the policy.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC